Modular Medical, Inc. (NASDAQ: MODD ) on Thursday announced that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system.
The update further expands the system’s functionality and provides users with greater flexibility and customization options in bolus dosing, an enhanced user interface (UI), and other software upgrades.
In July, the company submitted to the FDA a series of software enhancements to its Pivot insulin delivery system, providing users with more customization options and UI improvements, as well as other software upgrades.
"We are pleased that this clearance was received in advance of our planned fourth quarter launch. The cleared improvements represent the first in a series of enhancements and upgrades to the Pivot platform and were designed to expand the functionality and flexibility of Pivot for users, including the ability to customize the amount of insulin delivered with each button push," said Jeb Besser, CEO of Modular Medical.
In August, Modular Medical initiated the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026.
Read Next GeneralEXCLUSIVE: Modular Medical Advances Commercial Rollout With First Active Users Of Pivot Insulin Pump
Modular Medical says first patients begin using the Pivot insulin patch pump, starts collecting real-world data to support commercial adoption.
2 min read Read this articleTo support the launch, Modular Medical partnered with Inizio, a global commercialization partner.
MODD Stock Price Activity: Modular Medical shares were up 6.94% at $3.70 during premarket trading Thursday, according to Benzinga Pro data .
Read Next GeneralJeff Bezos' Blue Origin Wins NASA's $700M Mars Contract — Beats Rocket Lab in High-Stakes Space Race
Blue Origin won NASA’s $700M contract to build and operate a Mars communications network, expected to support missions by 2030.
3 min read Read this articlePhoto via Shutterstock
Trending Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News FDA General Top Stories Health Care Exclusives Market-Moving Exclusives Why It's Moving